Management of Opioid-Induced Hyperalgesia
The primary management strategy for opioid-induced hyperalgesia (OIH) is opioid dose reduction or opioid rotation to an alternative opioid, with adjuvant therapies such as ketamine or NMDA-receptor antagonists used to facilitate the transition and improve pain control. 1, 2
Recognition and Diagnosis
OIH presents as a paradoxical increase in pain sensitivity despite escalating opioid doses. Key clinical features to identify include:
- Progressive pain worsening with increasing opioid doses (particularly at very high doses - median 850 mg oral morphine equivalents reported in case series) 3
- Allodynia and hyperalgesia on physical examination - pain from normally non-painful stimuli 4
- Diffuse pain distribution that extends beyond the original pain site
- Rapid dose escalation with minimal analgesic response 4
Critical distinction: This is NOT opioid tolerance (which responds to dose increases) or pseudoaddiction (which responds to adequate pain control). OIH paradoxically worsens with dose escalation 5, 2.
Management Strategies
Three evidence-based approaches exist with similar success rates (57-79%) 3:
1. Opioid Rotation (72% success rate)
Switch to a different opioid at lower-than-expected equianalgesic doses 6, 1:
- Methadone is particularly effective due to its NMDA-antagonist properties and different receptor binding profile 6, 1
- Buprenorphine shows emerging promise - its partial agonist properties and high receptor affinity may reverse hyperalgesia 7
- Use conversion ratios conservatively - start at 50-75% of calculated equianalgesic dose due to incomplete cross-tolerance 6
Methadone conversion ratios (based on prior morphine dose) 6:
- <90 mg morphine: use 1:4 ratio
- 90-300 mg morphine: use 1:8 ratio
300 mg morphine: use 1:12 or higher ratio
2. Opioid Dose Reduction/Cessation (57% success rate)
Gradually taper opioids while managing withdrawal symptoms 1, 2:
- Taper slowly to avoid withdrawal (typically over 3-7 days for physical dependence symptoms) 2
- Pain improvement occurs rapidly once OIH is addressed (mean 8 days, range 1-28 days) 3
- Paradoxically, pain often improves with dose reduction - this confirms the diagnosis 2
3. Adjuvant Pharmacotherapy (79% success rate - highest efficacy)
Add NMDA-receptor antagonists while reducing opioid dose 1, 3:
Ketamine (most widely used) 3, 4:
- Low-dose infusions (0.1-0.5 mg/kg/hr)
- Particularly effective for rapid symptom control
- Allows for greater opioid dose reduction
Dexmedetomidine 3:
- Alpha-2 agonist with opioid-sparing effects
- Useful in perioperative/ICU settings
Other adjuvants to consider:
Practical Implementation Algorithm
Recognize OIH: Escalating pain despite increasing opioids + physical signs of hyperalgesia/allodynia
Choose strategy based on clinical context:
Monitor response: Pain should improve within 1-4 weeks 3
Critical Pitfalls to Avoid
- Do NOT increase opioid doses - this worsens OIH and creates a vicious cycle 2
- Do NOT mistake OIH for pseudoaddiction or drug-seeking behavior - these patients need LESS opioid, not more 5
- Do NOT abruptly discontinue opioids without managing withdrawal symptoms or providing alternative analgesia 2
- Avoid mislabeling as tolerance - tolerance responds to dose increases; OIH does not 5
Special Populations
Patients on buprenorphine/methadone maintenance 5:
- Continue baseline opioid agonist therapy (prevents withdrawal-induced hyperalgesia)
- Add short-acting full agonists for acute pain (higher doses needed due to receptor competition)
- Consider dividing buprenorphine into q6-8h dosing for analgesic effect
- Implement multimodal analgesia preemptively
- Use opioid-sparing techniques
- Monitor with functional pain scores, not just numeric ratings
The evidence consistently demonstrates that reducing or rotating opioids, rather than escalating them, resolves OIH symptoms - a counterintuitive but critical management principle 2, 3.